CRISPR/Cas9 knockout of DNMT1 using sgRNA (34) had a more negative impact on the growth of a synovial sarcoma cell line (HS-SY-II) compared with an osteosarcoma cell line (KHOS) (Figure 1D). Here, DNMT1 is linked to synovial sarcoma.